openPR Logo
Press release

Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics- Pipeline Analysis 2019, Clinical Trials & Results and Other Developments | Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC

04-02-2019 02:03 PM CET | Health & Medicine

Press release from: Pharma Proff

Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors

Glycogen synthase kinase 3 beta (GSK-3β) is an attractive target for the treatment of psychiatric disorders and neurodegenerative diseases. Many GSK-3β inhibitors have been developed for the treatment of different central nervous system disorders. But, for an effective therapy, high IC50 values should be avoided and ATP-competition should be reduced during enzyme-compound binding. Studies suggested that ATP non-competitive GSK-3 inhibitors such covalent inhibitors and allosteric modulators are emerging as a promising approach with better efficacy and safety.

Download the sample report @

Despite of many GSK-3β inhibitors in clinical studies, many challenges still remains. In a clinical study, certain adverse events caused by off-target activity of GSK-3β inhibitors were determined after the screening of compounds that bind to the ATP-competitive binding site conserved across a broad range of kinases. Thus, there is an urgent need of development of GSK-3β inhibitors that can selectively target individual pathways and differentiate between the non-phosphorylated and phosphorylated GSK-3β.

Get the detailed analysis @

Company like AMO Pharma Ltd. is in the process of developing AMO-02 as a small molecule which acts as a GSK-3β inhibitor for the treatment of congenital myotonic dystrophy.

Make enquiry before purchase @

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics- Pipeline Analysis 2019, Clinical Trials & Results and Other Developments | Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC here

News-ID: 1683603 • Views: 663

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for Glycogen

Insights on the Glycogen Synthase Kinase 3 Beta Market to 2027 | Industry Statis …
The global glycogen synthase kinase 3 beta market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Glycogen synthase kinase 3, or GSK-3 refers to a serine/threonine, proline-directed kinase that is associated with a diverse array of signaling pathways, which includes cellular adhesion and glycogen synthesis. The compounds derived from natural sources come mainly from plants or marine organisms, and include Indirubin, Hymenialdisine, Meridianins, Manzamines, Palinurin,
Glycogen Synthase Kinase 3 (GSK-3) Inhibitor Market 2020 Research and Clinical A …
Glycogen Synthase Kinase 3 (GSK-3) Inhibitor -Pipeline Insight, 2020 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Glycogen Synthase Kinase 3 (GSK-3) Inhibitor Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has
Glycogen Metabolism Disease Market Forecast by 2025: QY Research
This recently published report examines the global Glycogen Metabolism Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Glycogen Metabolism Disease market along with its drivers, restraints, and trends. It also classifies the market into different
Global Glycogen Storage Disorders (GSD) Clinical Trials Market 2021 Key Company …
Qyresearchreports include new market research report "Global Glycogen Storage Disorders (GSD) Clinical Trials Sales Market Report 2021" to its huge collection of research reports. The report here assembles exchange points of view having a place with the general Glycogen Storage Disorders (GSD) Clinical Trials market which verbalizes the present-day information and future exposures with reference to the dynamic forces at play. The prime explanation for the examination report is to offer
New Research Report Offers Pipeline Review of Glycogen Synthase Kinase 3 Beta in …
 GSK3B, also known as Glycogen Synthase Kinase 3 beta is basically an enzyme that is encoded by the GSK3B. It constitutively actuate protein kinase that goes about as a negative controller in the Wnt flagging, hormonal control of glucose homeostasis, and direction of interpretation elements and microtubules. According to this new research report, titled, “Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC or EC
Global Clinical Trials Review for Glycogen Storage Disorders (GSD), H2, 2017
"The Report Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" ​Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2017 Summary GlobalDatas clinical trial report, Glycogen Storage Disorders (GSD) Global Clinical Trials Review, H2, 2017" provides an overview of Glycogen Storage Disorders (GSD) clinical trials scenario. Get Sample copy of this Report @ ​